UPDATE | May 28, 2026
Why high concentration biologics demand a new approach to formulation science
High-concentration biologics continue to gain momentum, particularly for subcutaneous administration. But achieving stable, manufacturable formulations at high concentrations requires more than conventional formulation strategies.
In this whitepaper, Samsung Biologics introduces S-HiCon™, our proprietary platform designed to enable a more integrated, data-driven approach to high-concentration formulation development.
Key topics include:
- Scientific rationale behind the S-HiCon™ platform
- Early material generation strategies to support formulation development
- Structured excipient screening approaches and advanced analytical characterization capabilities
- A case study demonstrating successful formulation of an IgG1 monoclonal antibody at concentrations exceeding 200mg/mL
Discover how integrated formulation strategies can help address the growing complexity of high-concentration biologics development.
High-concentration biologics continue to gain momentum, particularly for subcutaneous administration. But achieving stable, manufacturable formulations at high concentrations requires more than conventional formulation strategies.
In this whitepaper, Samsung Biologics introduces S-HiCon™, our proprietary platform designed to enable a more integrated, data-driven approach to high-concentration formulation development.
Key topics include:
- Scientific rationale behind the S-HiCon™ platform
- Early material generation strategies to support formulation development
- Structured excipient screening approaches and advanced analytical characterization capabilities
- A case study demonstrating successful formulation of an IgG1 monoclonal antibody at concentrations exceeding 200mg/mL
Discover how integrated formulation strategies can help address the growing complexity of high-concentration biologics development.
Related Content